Phase I dose expansion data for M6620 (formerly VX-970), a first-in-class ATR inhibitor, combined with gemcitabine (Gem) in patients (pts) with advanced non-small cell lung cancer (NSCLC)
Authors
Plummer, RCook, Natalie
Arkenau, T
Melear, J
Redfern, C
Spira, A
Chung, K
Haddad, T
Ramalingam, S
Wesolowski, R
Dean, Emma J
Goddemeier, T
Falk, M
Shapiro, G
Affiliation
Northern Centre for Cancer Care, Freeman Hospital, Newcastle Upon Tyne, UKIssue Date
2018
Metadata
Show full item recordCitation
Plummer R, Cook N, Arkenau T, Melear J, Redfern C, Spira AI, et al. 1437P Phase I dose expansion data for M6620 (formerly VX-970), a first-in-class ATR inhibitor, combined with gemcitabine (Gem) in patients (pts) with advanced non-small cell lung cancer (NSCLC). Ann Oncol. 2018;29(suppl_8):519.Journal
Annals of OncologyDOI
10.1093/annonc/mdy292.059Additional Links
https://dx.doi.org/10.1093/annonc/mdy292.059Type
Meetings and ProceedingsLanguage
enae974a485f413a2113503eed53cd6c53
10.1093/annonc/mdy292.059